2024-05-09 06:55:33
Gautam Adani has made a lot of changes in his business with time. Today we are going to tell you about Adani’s new app ‘Adani One’. With its help, you are going to get a lot of help from train ticket booking to hotel booking. Besides, its interface is also very easy which is going to give you a different experience. But before using it, you should know about some things-
Along with the app, you can also book tickets from the website. Users are also being given the option of booking flight, train, hotel and bus tickets. From here you can get any information regarding flights and trains. Also, booking will also become easier. iOS users can easily download this app. You can search for the train by going to the App Store.
To book tickets from the site, you will have to go directly to Adani One. After going here you will see many options. But first of all you have to select whose ticket you want to book. Suppose you want to book a train ticket, then you will have to enter the travel details. After doing this you will get the details of all the trains.
How does the app work-IRCTC is an authorized train ticket booking app. That means, if you book train tickets from here, you will not face much problem. Apart from this, hotel booking can also be availed from here. Remember that while booking anything, you will also have to take care of payment. The information revealed so far shows that other options will also be added in the future. Very soon the option of movie ticket booking can also be given in it.
Related
Tesla Quietly Removes All U.S. Job Postings
Tesla is a massive company, employing 140,000 people as of late last year. But over the past month, layoffs have torn through the electric vehicle maker — and now a hiring freeze appears to be in effect in North America.
video instream-permalink instream-native-video–mobile”>
video-html5-playlist” data-playlist=”195689,193563,193795″ data-current=”195689″>
video-html5-loaded”>
video-html5-player”>
video-html5 autoplay muted mobile” data-video-id=”195689″ data-monetizable=”true” data-position=”sidebar” data-video-title=”Did Elon Musk Regret Buying Twitter? | Walter Isaacson Interview” data-video-blog-id=”4″ data-video-network=”gizmodo” data-video-duration=”214″>
video-top-bar”>
Did Elon Musk Regret Buying Twitter? | Walter Isaacson Interview
video disablepictureinpicture=”” muted=”” playsinline=”” width=”100%” height=”100%” crossorigin=”anonymous” preload=”none” style=”max-height:none”>
As of Wednesday, just three positions were listed on Tesla’s job board. They’re all for jobs to join its manufacturing development program in Texas, Californiaor Nevada, a seven-week training program that promises the “opportunity to transition into a full-time Production Associate” at a Tesla factory.
That’s a far cry from the more than 3,400 postings that were offered across the United States, Mexico, Canada and Puerto Rico as of May 1, according to an archived version of Tesla’s career webpage. (Puerto Rico is listed separately despite being a U.S. territory.) The bulk of those positions were in California, Texas, and Nevada, where the company has sprawling “gigafactories.” Many of the jobs were still posted on Tesla’s website as recently as Tuesday.
On LinkedIn, Tesla advertises 326 jobs. Most are located in China, with a few others in Europe and at least one in the Dominican Republic. Just one, for the manufacturing development programappears to be located in the U.S.
Tesla did not immediately respond to a request for comment Wednesday.
This marks the second time that Tesla has almost entirely wiped out its job postings since it began laying off thousands of workers on April 16. Drive Tesla reported later that day that almost all jobs postings across the company’s North American operations had been removed. Just days later, the job board had been restored with thousands of postings.
“With [Tesla’s] rapid growth there has been duplication of roles and job functions in certain areas,” CEO Elon Musk wrote to employees last month as he informed them of job cuts. “As we prepare the company for our next phase of growth, it is extremely important to look at every aspect of the company for cost reductions and increasing productivity.”
“There is nothing I hate more, but it must be done,” he added, expressing his thanks and well wishes for the — at least — 14,000 workers being laid off.
In recent weeks, Musk has been less apologetic about the headcount reductions. In an email to senior Tesla executives, first reported by The InformationMusk said he wanted to be “absolutely hardcore” about issuing more job cuts.
He also said he would ask any executive who retained more than three workers who “don’t obviously pass the excellent, necessary and trustworthy test” to resign. At least three executives departed the company later that week.
More than 20,000 people may have been laid off in that first round of headcount reductions, Bloomberg reported last month. Summer internship offers have been revoked just weeks before their start dates. Almost the entire Supercharger division has been cutdespite Tesla being a major player in the EV charging industry, and the public policy team has been greatly reduced.
Tesla entered its fourth consecutive week of layoffs on Monday, with the latest round affecting service advisers, human resource workers, product engineers, industrializing engineers, and more.
“As of 7:24 PM last night, Elon Musk incorporated me into their massive layoff crew costing me my career, my health benefits, and my sanity,” one now-former Tesla employee wrote Monday on LinkedIn. “Nothing but an email to make us aware of how disposable we were as employees.”
At least six high-profile executives have either already resigned or plan to later this year, including former senior vice president of powertrain and energy Drew Baglinoand senior director of human resources for North America Allie Arebalo.
This article originally appeared on Quartz.
#Tesla #Quietly #Removes #U.S #Job #Postings
– 2024-05-09 07:44:46
Related posts:
Study suggests critical connection between residual FLT3-ITD mutations in remission and post-transplant outcomes in AML
2024-05-09 02:54:51
A groundbreaking research study,1 sequencing of DNA samples from the Pre-MEASURE study2 strongly indicates that detection ofresidual internal tandem duplication (ITD) mutations of FLT3 in the blood of adult individuals with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after allogeneic hematopoietic cell transplantation (HCT).
This follow-up study tested for measurable residual disease (MRD) on the DNA of 537 individuals withLMA with FLT3 -ITD mutation from the Pre-MEASURE study using the RUO kitof tests FLT3 ITD MRD from Invivoscribe and bioinformatics software. Their findings highlight the likely importance ofFLT3 -Residual ITD at first CR in predicting relapse and post-transplant mortality.
An important finding of this research study was that individuals with AML with FLT3 -Residual ITD detected before allogeneic HCT tended to have an elevated risk of relapse and post-transplant mortality, with a dose-dependent correlation within this study population.
Hourigan, director of the Virginia Tech FBRI Cancer Research Center in Washington, D.C. and the study’s principal investigator, noted, “This research highlights the value of pre-transplant testing to FLT3 -Residual ITD in adults with AML. The association of MRD test results with post-transplant outcomes opens up the potential to refine treatment strategies to improve survival.”
Going forward, the study calls for more research to explore alternative approaches for high-risk populations who may not benefit from current standard care protocols.
Jeff Miller, CEO/CSO of Invivoscribe, commented: “We are excited to observe the remarkable association of clinical outcomes that have been so clearly delineated using our testing and software-only research. This research study increases our understanding of AML monitoring and treatment. ”
About Invivoscribe
Invivoscribe is a global, vertically integrated biotechnology company dedicated to improving lives with precision diagnostics.®). For nearly thirty years, Invivoscribe has improved the quality of healthcare around the world by offering high-quality reagents, tests, bioinformatics tools and standardized services to advance the field of precision medicine. Invivoscribe has a successful track record of partnering with global pharmaceutical companies interested in developing and commercializing companion diagnostics and offers expertise in regulatory and laboratory services. By providing distributable kits as well as clinical trial services through its globally located clinical laboratory subsidiaries (LabPMM), Invivoscribe is an ideal partner in diagnostic and clinical trial development, regulatory submission and commercialization. For additional information, visit www.invivoscribe.com or contact us via email [email protected] and follow us on Linked In.
1. Measurable ResidualFLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia, Dillonet al JAMA Oncology, published online May 2, 2024.
2. DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant, Dillon et al JAMA 2023; 329 (9): 745-755
The original language text of this announcement is the official authorized version. Translations are provided as a facility only and must refer to the text in the original language, which is the only version of the text that has legal effect.
View original version on businesswire.com:
Contact:
[email protected]
Source: BUSINESS WIRE
1715226213
#Study #suggests #critical #connection #residual #FLT3ITD #mutations #remission #posttransplant #outcomes #AML
Related posts: